Post job

Pharma Belgium company history timeline

1831

Menarini Benelux N.V./S.A., De Kleetlaan 3, B-1831 Machelen

1886

Menarini was established more than 125 years ago (1886) in a small laboratory in Naples, Italy.

1933

By 1933 Constant Janssen had acquired the exclusive right to import Richter's products into Belgium, The Netherlands, and the Belgian Congo, establishing his own business, in addition to his medical practice.

1950

The main development is reviewed from 1950 to now including: regulation, professional association roles, agreement and continuing education, development of clinical pharmacy, and updating of university training program.

1951

Returning to Europe, Janssen completed his medical studies at Leuven, then earned his medical degree at the University of Ghent in 1951.

1953

Created in 1953, this professional and scientific association represents all pharmacists who work in hospital institutions, whether private or public, university, general or psychiatric.

Returning to Turnhout in 1953, Janssen had set up his own laboratory on the third floor of his father's company.

1954

Janssen's work consisted of synthesizing molecules, and by 1954, Janssen had synthesized his fifth molecule--R5, better known as ambucetamide.

1954 The company develops its first successful compound, ambucetamide.

1955

By 1955, Janssen had released the drug under the brand name Neomeritime.

1956

1956 The company changes its name to NV Laboratoria Pharmaceutica Doctor C. Janssen.

1959

In 1959, Janssen launched a new drug for the treatment of schizophrenia, called haloperidol.

In 1959, for example, Johnson & Johnson had acquired Switzerland's Cilag-Chemie and the United States' McNeil Laboratories.

1961

1961 Janssen is acquired by Johnson & Johnson.

1963

Released in 1963, that drug became the world's most prescribed anaesthetic.

1964

When Doctor Alberto Aleotti was appointed to the head of Menarini in 1964, it had 188 employees and ranked 352nd in the ranking of European pharmaceutical companies.

1964 The company's name is changed to Janssen Pharmaceutica.

1972

1972 A United States subsidiary is established in the J&J facility.

1978

The first appeared in 1978 in the Moniteur , the official journal that publishes all laws and RDs, requiring the presence of a pharmacist in all hospitals of the Kingdom (RD of 19 October 1978) . At the same time, the Belgian universities introduced a program of specialization in hospital pharmacy.

1980

In 1980, the company entered the United States, establishing a sales network where previously it had marketed its products through other J&J subsidiaries or under third-party brands.

1980 The company launches the first technology transfer agreement in China.

1983

Janssen also has maintained a production presence in China since 1983, through its joint venture Xian-Janssen Pharmaceutical Co.

1987

At that time it was only the second subsidiary after Spain.The development of the pharmaceutical activities of Menarini Benelux N.V./S.A. started in September 1987.

1989

In 1989 two regional associations were created: one for Dutch speakers (the Flemish Association of Hospital Pharmacists—VZA) and the other for French speakers (the French-speaking Association of Belgian Hospital Pharmacists—AFPHB) , following the federal trend within the Kingdom.

That partnership began construction of a factory in Xian, which launched production in 1989.

1990

1990 The company merges its global sales and marketing network with those of sister companies Cilag and J&J Biotechnology, creating Janssen-Cilag.

1991

1991 Paul Janssen retires.

2003

The RD of 11 June 2003 describes the minimum program (900 h) of theoretical training and work experience.

The particular title of hospital pharmacist was also created in 2003.

2004

2004 Paul Janssen dies at age 77.

2007

In March 2007, Rudy Demotte, the Minister of Social Affairs and Public Health at the time, launched a call for clinical pharmacy projects from general and university hospitals in Belgium.

2008

Two further reports were required before the end of the projects on 31 December 2008.

2010

Once again, 27 projects were selected and officially launched during an inaugural session in Brussels on 4 June 2010.

In September 2010, a new training program for hospital pharmacists was established by all of the universities in Belgium.

2013

On 10 May 2013, the Belgian Association of Hospital Pharmacists (BAHP) celebrated 60 years of existence and became a Royal Society.

2014

In June 2014, the NN-PTC concluded that the experiences of the projects in place were conclusive.

They decided, on the 1 July 2014, to inject a budget for 0.25 full-time equivalent (FTE) of clinical pharmacists per 200 beds in general and academic/university hospitals.

2018

The Menarini Group, led by the Aleotti family, decided in March 2018 to entrust as early as June the Chaimanship of the company to an external manager coming from another large multinational, Doctor Eric Cornut.

Work at Pharma Belgium?
Share your experience
Founded
-
Company founded
Get updates for jobs and news

Rate Pharma Belgium's efforts to communicate its history to employees.

Zippia waving zebra

Pharma Belgium jobs

Do you work at Pharma Belgium?

Does Pharma Belgium communicate its history to new hires?

Zippia gives an in-depth look into the details of Pharma Belgium, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Pharma Belgium. The employee data is based on information from people who have self-reported their past or current employments at Pharma Belgium. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Pharma Belgium. The data presented on this page does not represent the view of Pharma Belgium and its employees or that of Zippia.

Pharma Belgium may also be known as or be related to Pharma Belgium.